KENDALL KAUFMAN: Open Payments
NPI 1679828859 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,141 in 120 payments from 12 companies in 2025. Trend: 2023 $1,059 · 2024 $1,135 · 2025 $2,141
Food & beverage: $2,028Education: $113
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $565 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $448 |
| Teva Pharmaceuticals USA, Inc. | 16 | $320 |
| E.R. Squibb & Sons, L.L.C. | 18 | $202 |
| Alkermes, Inc. | 11 | $195 |
| Janssen Pharmaceuticals, Inc | 11 | $191 |
| Vanda Pharmaceuticals Inc. | 4 | $87 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
Products named: INGREZZA, CAPLYTA, COBENFY, INVEGA SUSTENNA, ARISTADA, UZEDY, FANAPT, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
